Can Combination Immunotherapy Really Treat Cancer?

Combination immunotherapy refers to using more than one immune checkpoint inhibitor together—commonly anti-PD-1 (e.g., nivolumab) and anti-CTLA-4 (e.g., ipilimumab)—to strengthen the body’s immune response against cancer cells.

What Types of Cancer Can Be Treated?

1. Melanoma

ใช้ nivolumab + ipilimumab เป็น first-line ในผู้ป่วย BRAF-negative หรือผู้ที่จำกัดไม่ใช้ targeted therapy

รายงานว่า survival rate 10 ปี สูงถึง 52% สำหรับผู้ใช้ยา 2 ตัวร่วมกัน

2. Kidney Cancer (Renal Cell Carcinoma)

Nivolumab+ipilimumab ได้รับการรับรองในผู้ป่วย metastatic กลุ่ม intermediate–poor risk

3.Non‑Small Cell Lung Cancer (NSCLC)

Approved for patients with PD-L1 ≥1%, or in combination with chemotherapy depending on stage and mutation profile.

4.Colorectal Cancer (MSI‑H/dMMR)

Applicable to patients with MSI-H/dMMR genetic profiles, which respond better to immune therapies.

5.Hepatocellular Carcinoma

May be used after progression on first-line targeted therapy like sorafenib.

Why Use Combination Therapy?

• Dual checkpoint blockade enhances T-cell activation at different points in the immune cycle.
• Provides more robust and durable responses compared to monotherapy.

Precautions

• More severe side effects such as hepatitis, enteritis, thyroid problems, etc. require intensive monitoring and evaluation.
• It is recommended to be treated by an experienced team and have an automatic symptom tracking system.